Literature DB >> 20959811

Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells.

Jan-Michael Prill1, Sigrid Espenlaub, Ulrike Samen, Tatjana Engler, Erika Schmidt, Francesco Vetrini, Amanda Rosewell, Nathan Grove, Donna Palmer, Philip Ng, Stefan Kochanek, Florian Kreppel.   

Abstract

In vivo gene transfer with adenovirus vectors would significantly benefit from a tight control of the adenovirus-inherent liver tropism. For efficient hepatocyte transduction, adenovirus vectors need to evade from Kupffer cell scavenging while delivery to peripheral tissues or tumors could be improved if both scavenging by Kupffer cells and uptake by hepatocytes were blocked. Here, we provide evidence that a single point mutation in the hexon capsomere designed to enable defined chemical capsid modifications may permit both detargeting from and targeting to hepatocytes with evasion from Kupffer cell scavenging. Vector particles modified with small polyethylene glycol (PEG) moieties specifically on hexon exhibited decreased transduction of hepatocytes by shielding from blood coagulation factor binding. Vector particles modified with transferrin or, surprisingly, 5,000 Da PEG or dextran increased hepatocyte transduction up to 18-fold independent of the presence of Kupffer cells. We further show that our strategy can be used to target high-capacity adenovirus vectors to hepatocytes emphasizing the potential for therapeutic liver-directed gene transfer. Our approach may lead to a detailed understanding of the interactions between adenovirus vectors and Kupffer cells, one of the most important barriers for adenovirus-mediated gene delivery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959811      PMCID: PMC3017454          DOI: 10.1038/mt.2010.229

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  37 in total

1.  Capsomer-specific fluorescent labeling of adenoviral vector particles allows for detailed analysis of intracellular particle trafficking and the performance of bioresponsive bonds for vector capsid modifications.

Authors:  Sigrid Espenlaub; Stéphanie Corjon; Tatjana Engler; Carolin Fella; Manfred Ogris; Ernst Wagner; Stefan Kochanek; Florian Kreppel
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

2.  Methods for the production of helper-dependent adenoviral vectors.

Authors:  Donna J Palmer; Philip Ng
Journal:  Methods Mol Biol       Date:  2008

3.  Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement.

Authors:  Zhili Xu; Jie Tian; Jeffrey S Smith; Andrew P Byrnes
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

4.  Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver.

Authors:  Frédéric Vigant; Delphyne Descamps; Betsy Jullienne; Stéphanie Esselin; Elisabeth Connault; Paule Opolon; Thierry Tordjmann; Emmanuelle Vigne; Michel Perricaudet; Karim Benihoud
Journal:  Mol Ther       Date:  2008-06-17       Impact factor: 11.454

5.  An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood.

Authors:  A Danielsson; G Elgue; B M Nilsson; B Nilsson; J D Lambris; T H Tötterman; S Kochanek; F Kreppel; M Essand
Journal:  Gene Ther       Date:  2010-03-11       Impact factor: 5.250

6.  Targeting of adenovirus vectors to the LRP receptor family with the high-affinity ligand RAP via combined genetic and chemical modification of the pIX capsomere.

Authors:  Stéphanie Corjon; Andreas Wortmann; Tatjana Engler; Nico van Rooijen; Stefan Kochanek; Florian Kreppel
Journal:  Mol Ther       Date:  2008-08-19       Impact factor: 11.454

7.  Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo.

Authors:  O Kalyuzhniy; N C Di Paolo; M Silvestry; S E Hofherr; M A Barry; P L Stewart; D M Shayakhmetov
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

8.  Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus.

Authors:  Konstantin Doronin; Elena V Shashkova; Shannon M May; Sean E Hofherr; Michael A Barry
Journal:  Hum Gene Ther       Date:  2009-09       Impact factor: 5.695

9.  Adenovirus serotype 5 hexon mediates liver gene transfer.

Authors:  Simon N Waddington; John H McVey; David Bhella; Alan L Parker; Kristeen Barker; Hideko Atoda; Rebecca Pink; Suzanne M K Buckley; Jenny A Greig; Laura Denby; Jerome Custers; Takashi Morita; Ivo M B Francischetti; Robson Q Monteiro; Dan H Barouch; Nico van Rooijen; Claudio Napoli; Menzo J E Havenga; Stuart A Nicklin; Andrew H Baker
Journal:  Cell       Date:  2008-02-08       Impact factor: 41.582

10.  Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer.

Authors:  Joanne Morrison; Simon S Briggs; Nicola K Green; Clemens Thoma; Kerry D Fisher; Sean Kehoe; Leonard W Seymour
Journal:  Hum Gene Ther       Date:  2009-03       Impact factor: 5.695

View more
  31 in total

1.  Magnetic nanoparticles enhance adenovirus transduction in vitro and in vivo.

Authors:  Cédric Sapet; Christophe Pellegrino; Nicolas Laurent; Flavie Sicard; Olivier Zelphati
Journal:  Pharm Res       Date:  2011-12-07       Impact factor: 4.200

2.  Encapsulation of adenovirus serotype 5 in anionic lecithin liposomes using a bead-based immunoprecipitation technique enhances transfection efficiency.

Authors:  Natalie Mendez; Vanessa Herrera; Lingzhi Zhang; Farah Hedjran; Ralph Feuer; Sarah L Blair; William C Trogler; Tony R Reid; Andrew C Kummel
Journal:  Biomaterials       Date:  2014-08-22       Impact factor: 12.479

3.  Real-time recording of circadian liver gene expression in freely moving mice reveals the phase-setting behavior of hepatocyte clocks.

Authors:  Camille Saini; André Liani; Thomas Curie; Pascal Gos; Florian Kreppel; Yann Emmenegger; Luigi Bonacina; Jean-Pierre Wolf; Yves-Alain Poget; Paul Franken; Ueli Schibler
Journal:  Genes Dev       Date:  2013-07-01       Impact factor: 11.361

4.  miRNA-mediated silencing in hepatocytes can increase adaptive immune responses to adenovirus vector-delivered transgenic antigens.

Authors:  Matthias W Kron; Sigrid Espenlaub; Tatjana Engler; Reinhold Schirmbeck; Stefan Kochanek; Florian Kreppel
Journal:  Mol Ther       Date:  2011-05-10       Impact factor: 11.454

Review 5.  Helper-dependent adenoviral vectors for liver-directed gene therapy.

Authors:  Nicola Brunetti-Pierri; Philip Ng
Journal:  Hum Mol Genet       Date:  2011-04-05       Impact factor: 6.150

Review 6.  Gene therapy with helper-dependent adenoviral vectors: lessons from studies in large animal models.

Authors:  Nicola Brunetti-Pierri; Philip Ng
Journal:  Virus Genes       Date:  2017-06-07       Impact factor: 2.332

7.  Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting.

Authors:  Franziska Jönsson; Claudia Hagedorn; Florian Kreppel
Journal:  J Vis Exp       Date:  2018-10-26       Impact factor: 1.355

8.  Adenovirus immunity: X marks the spot.

Authors:  Masataka Suzuki; Cliona M Rooney
Journal:  Mol Ther       Date:  2012-12       Impact factor: 11.454

Review 9.  Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5.

Authors:  Franziska Jönsson; Florian Kreppel
Journal:  Virus Genes       Date:  2017-07-28       Impact factor: 2.332

10.  Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement.

Authors:  Zhili Xu; Qi Qiu; Jie Tian; Jeffrey S Smith; Gina M Conenello; Takashi Morita; Andrew P Byrnes
Journal:  Nat Med       Date:  2013-03-24       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.